QCM
JAZZ icon

Qsemble Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Qsemble Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$230K Buy
+1,217
New +$213K 0.02% 423
2025
Q3 		– Sell
-3,651
Closed -$387K – 527
2025
Q2 		$387K Buy
3,651
+49
+1% +$5.32K 0.04% 347
2025
Q1 		$447K Buy
+3,602
New +$470K 0.05% 317

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Qsemble Capital Management's JAZZ Position: Q1 2026 in Review

Qsemble Capital Management opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 1,217 shares worth $230K. The stake represents 0.02% of the portfolio and ranks #423 among its holdings. This is a return to the name: Qsemble Capital Management previously reported a position in JAZZ as recently as Q2 2025.

Qsemble Capital Management first reported a position in JAZZ in Q1 2025 and has held it in 3 quarters since. The position peaked at $447K in Q1 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Qsemble Capital Management held 1,217 shares of Jazz Pharmaceuticals worth $230K as of Q1 2026.
  • Jazz Pharmaceuticals was a new Qsemble Capital Management position in Q1 2026.
  • Jazz Pharmaceuticals made up 0.02% of Qsemble Capital Management's portfolio in Q1 2026, its #423 holding.
  • Qsemble Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Qsemble Capital Management's Jazz Pharmaceuticals position peaked at $447K in Q1 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Qsemble Capital Management's 13F filing for Q1 2026, filed 7 May 2026.